Bio Pharma Dive
DECEMBER 1, 2023
The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts.
Pharmaceutical Technology
DECEMBER 1, 2023
Partnership deals involving psychedelic drugs saw a 500% growth in total deal volume from 2019 to 2023 year-to-date (YTD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
DECEMBER 1, 2023
The company won’t continue development of a twice-daily dose of its experimental weight loss medicine danuglipron after study data showed high rates of side effects.
Pharmaceutical Technology
DECEMBER 1, 2023
Hot on the heels of the designation, Orchard Therapeutics is pressing ahead with a multi-centre trial for the candidate with a start date in December.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
DECEMBER 1, 2023
The Tang Capital-controlled company is bidding for LianBio shortly after making takeover offers for Rain Oncology and Theseus Pharmaceuticals.
Pharmaceutical Technology
DECEMBER 1, 2023
Biocon subsidiary Biocon Biologics has successfully integrated Viatris' biosimilars business in 31 countries in Europe.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 1, 2023
The SMC and NICE have recommended the use of AstraZeneca’s durvalumab to treat advanced biliary tract cancers in England and Scotland.
Pharma Times
DECEMBER 1, 2023
Every year, around 55,000 women in the UK are diagnosed with the condition - News - PharmaTimes
Pharmaceutical Technology
DECEMBER 1, 2023
Phenomic will utilise its single-cell RNA transcriptomics programme to develop cancer therapies in collaborations with Astellas and Boehringer.
pharmaphorum
DECEMBER 1, 2023
FDA starts review of Padcev/Keytruda for bladder cancer Phil.
Pharmaceutical Technology
DECEMBER 1, 2023
The US FDA has accepted Merck’s new sBLA for Keytruda plus Padcev to treat adults with urothelial carcinoma (la/mUC) for review.
pharmaphorum
DECEMBER 1, 2023
How to advance more late-stage neuroscience drugs to regulatory approval Mike.
Pharmaceutical Technology
DECEMBER 1, 2023
Novo Nordisk is continuing legal action against compounding pharmacies selling off-brand Ozempic which it claims are adulterated.
Fierce Pharma
DECEMBER 1, 2023
Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition law, according to a release from the country's government.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
DECEMBER 1, 2023
Biora Therapeutics announced FDA clearance for a Phase I trial for its ulcerative colitis therapy, BT-600.
pharmaphorum
DECEMBER 1, 2023
Cybin preps for ph3 as psychedelic clears depression trial Phil.
Pharmaceutical Technology
DECEMBER 1, 2023
Teva and Sanofi have concluded a collaboration deal for co-developing anti-tumour necrosis factor-like ligand 1A (TL1A) therapy, TEV’574.
Pharmaceutical Commerce
DECEMBER 1, 2023
In clinical trials, Keytruda plus Padcev lowered the risk of disease progression or death by 55% compared with chemotherapy in adult patients with locally advanced or metastatic urothelial carcinoma.
pharmaphorum
DECEMBER 1, 2023
MSD, Amgen back patient data specialist Culmination Bio Phil.
Fierce Pharma
DECEMBER 1, 2023
After a hard-fought battle for FDA approval, AstraZeneca has hit another setback on its quest to turn its potassium-reduction drug Lokelma into a blockbuster. | AstraZeneca has put the kibosh on two late-stage Lokelma trials testing the hyperkalemia drug in patients with heart and kidney diseases. The studies were called off due to “substantially increased enrollment times and low event rates,” AZ said Friday.
Intouch Solutions
DECEMBER 1, 2023
Recently, Ad Forum published an article highlighting five campaigns it found to be “ Raising the Bar for Health Equity in Advertising.” One was our ongoing work with The Chrysalis Initiative, a nonprofit working to eliminate racial disparities in breast cancer treatment. This alliance dates back to 2021, but in 2023, as Fierce Pharma put it, we “ roared back from rejection to craft a Cannes-winning campaign hospitals couldn’t ignore.
Fierce Pharma
DECEMBER 1, 2023
In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. | In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
DECEMBER 1, 2023
AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease. The STABILIZE-CKD and DIALIZE-Outcomes studies – part of AZ’s CRYSTALIZE programme for the drug – have been shelved because patients were being enrolled into them more slowly than hoped for, and clinical events were occurring at a lower rate than expected.
XTalks
DECEMBER 1, 2023
Since its debut in 1937, Kraft Mac & Cheese has become a beloved fixture in American homes. Known for its easy-to-prepare blue box meals, Kraft Mac & Cheese sells over one million boxes daily. This culinary icon is so ingrained in North American culture that it’s even dubbed Canada’s unofficial national dish. Now, in an era where dairy alternatives are soaring in popularity, Kraft Mac & Cheese is getting a plant-based makeover.
Fierce Pharma
DECEMBER 1, 2023
Texas attorney general Ken Paxton is going after Pfizer—again. | Texas attorney general Ken Paxton is going after Pfizer—again. Less than two weeks after documents were unsealed showing that Texas has accused Pfizer and manufacturer Tris Pharma of providing a compromised ADHD medicine to the state, Paxton has sued Pfizer for “unlawfully misrepresenting the effectiveness” of the company’s COVID-19 vaccine.
Outsourcing Pharma
DECEMBER 1, 2023
The first six companies enter the Deep Tech Lab - Quantum start-up accelerator at BioInnovation Institute (BII) to unlock the potential in quantum science
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
BioPharma Reporter
DECEMBER 1, 2023
AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.
Drug Patent Watch
DECEMBER 1, 2023
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Crucial Data Soutions
DECEMBER 1, 2023
The clinical research industry is currently dealing with a great deal of uncertainty, with various solutions providers announcing layoffs often. The post In a Time of Uncertainty for Clinical Researchers, Reliable Partners are Vital appeared first on Crucial Data Solutions.
Drug Patent Watch
DECEMBER 1, 2023
Annual Drug Patent Expirations for ANORO+ELLIPTA Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are fourteen patents… The post New patent for Glaxosmithkline drug ANORO ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
278 
Let's personalize your content